Erica Stringer-Reasor
Overview
Explore the profile of Erica Stringer-Reasor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reh N, Caston N, Williams C, Dwarampudi S, Elkhanany A, Khoury K, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):2038-2044.
PMID: 39653947
Introduction: Therapeutic clinical trials frequently lack diverse representation, hindering generalizability and exacerbating preexisting disparities in clinical outcomes. This study explored associations between breast cancer patient demographics, clinical trial eligibility, and...
2.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
3.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
4.
Bostany G, Chen Y, Francisco L, Dai C, Meng Q, Sparks J, et al.
J Clin Oncol
. 2024 Jun;
43(1):32-45.
PMID: 38833638
Purpose: Cardiac dysfunction is the leading cause of mortality among 10-year breast cancer survivors. Limited information regarding long-term risks of cardiac dysfunction after cardiotoxic therapy (anthracyclines, trastuzumab/pertuzumab, radiation) has precluded...
5.
Taye A, Elkhanany A, Stringer-Reasor E
Clin Adv Hematol Oncol
. 2024 May;
22(4):175-182.
PMID: 38739720
Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a large portion attributed to lower...
6.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Jo Chien A, et al.
Clin Cancer Res
. 2023 Dec;
30(4):729-740.
PMID: 38109213
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients...
7.
Kalinsky K, Accordino M, Chiuzan C, Mundi P, Sakach E, Sathe C, et al.
J Clin Oncol
. 2023 May;
41(24):4004-4013.
PMID: 37207300
Purpose: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic...
8.
Curigliano G, Shapiro G, Kristeleit R, Abdul Razak A, Leong S, Alsina M, et al.
Br J Cancer
. 2023 Jan;
128(2):400.
PMID: 36697966
No abstract available.
9.
Lang J, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):128.
PMID: 36456573
HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with...
10.
Curigliano G, Shapiro G, Kristeleit R, Abdul Razak A, Leong S, Alsina M, et al.
Br J Cancer
. 2022 Nov;
128(1):30-41.
PMID: 36335217
Background: This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours. Methods: Patients with various malignancies were administered gedatolisib...